Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure (ACLF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01074645 |
Recruitment Status :
Completed
First Posted : February 24, 2010
Last Update Posted : February 24, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background: Reactivation of hepatitis B is a well-characterized syndrome marked by the abrupt reappearance or rise of hepatitis B virus (HBV) DNA in the serum of a patient with previously inactive or resolved HBV infection. Reactivation can be spontaneous, but is most commonly triggered by cancer chemotherapy, immune suppression, or alteration in immune function. Spontaneous acute exacerbation of chronic hepatitis B infection is seen with a cumulative probability of 15±37% after 4 years of follow-up.2 Significant number of patients of spontaneous acute exacerbation of chronic hepatitis B may present with very high ALT levels, jaundice and liver failure.3 This condition should be defined as acute-on-chronic liver failure (ACLF) according to a recent Asia-Pacific consensus recommendation.
The short term prognosis of patients of spontaneous acute exacerbation of chronic hepatitis B leading to ACLF like presentation is extremely poor, with a mortality of 30-70% in different series.8,9,10 Liver transplantation has been the only definitive therapy available to salvage this group of patients. However ,this is not readily available and affordable. Another therapeutic option is antiviral therapy but has limited data. The efficacy of lamivudine was evaluated and compared by historical control but was not found to be beneficial.8,9,10 However ,a study from Taiwan showed a survival benefit in a subgroup of patients who were on lamivudine and had baseline bilirubin below 342 mmol/L (20 mg/dL).11 Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in suppressing hepatitis B virus replication.12 Tenofovir has also shown excellent activity against HBV in both LAM- naïve and LAM-resistant patients.13,14. Its efficacy has not been evaluated in patients of reactivation of hepatitis B who present as ACLF Hypothesis: The investigators hypothesis that Tenofovir reduces the morbidity and mortality in patients with Spontaneous reactivation of hepatitis B by reducing HBV DNA.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute on Chronic Liver Failure Hepatitis B | Drug: Tenofovir disoproxil fumarate (TDF) | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 27 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Tenofovir Reduces Morbidity and Mortality in Patients With Spontaneous Reactivation of Hepatitis B Presenting as Acute-on-chronic Liver Failure (ACLF): A Randomized Placebo Controlled Trial |
Study Start Date : | November 2007 |
Actual Primary Completion Date : | June 2009 |
Actual Study Completion Date : | October 2009 |

Arm | Intervention/treatment |
---|---|
No Intervention: Placebo
Placebo was the multivitamin capsule which was similar in appearance as of Tenofovir disoproxil fumarate and was given once a day till 3 month.
|
Drug: Tenofovir disoproxil fumarate (TDF)
Tenofovir 300mg/day for 3 month |
Active Comparator: Tenofovir disoproxil fumarate (TDF)
Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in suppressing hepatitis B virus replication. Tenofovir has also shown excellent activity against HBV in both LAM- naïve and LAM-resistant patients. Its efficacy has not been evaluated in patients of reactivation of hepatitis B who present as ACLF
|
Drug: Tenofovir disoproxil fumarate (TDF)
Tenofovir 300mg/day for 3 month |
- Reduction in HBV DNA levels, survival [ Time Frame: 3 Month ]
- Improvement in CTP, MELD scores [ Time Frame: 3 Month ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years to 75 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Reactivation of chronic hepatitis B characterized by rise in ALT level >5 times upper limit of normal along with HBV DNA level >105 copies/ml (~1.8x104 IU/ml) presenting as ACLF
- Acute hepatic insult
- Jaundice (bilirubin ≥5 mg/dL) and coagulopathy (INR>1.5)
- Complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease.
Exclusion Criteria:
- Superinfection with other viruses (Hepatitis E, A, D and C)
- Coexistent hepatocellular carcinoma (HCC)
- Portal vein thrombosis
- Coexistent renal impairment
- Pregnancy
- Co-infection with HIV infection or Patients received previous course of any antiviral
- Immunomodulator or cytotoxic/immunosuppressive therapy for chronic hepatitis or other illness within at least the preceding 12 month.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01074645
India | |
Department of Gastroenterology, GB Pant Hospital, | |
New Delhi, Delhi, India, 110002 |
Principal Investigator: | Shiv K Sarin, MD,DM | G.B. Pant Hospital, New Delhi, India |
Responsible Party: | Shiv K Sarin, G.B. Pant Hospital, New Delhi, India |
ClinicalTrials.gov Identifier: | NCT01074645 |
Other Study ID Numbers: |
Hitendra garg |
First Posted: | February 24, 2010 Key Record Dates |
Last Update Posted: | February 24, 2010 |
Last Verified: | October 2009 |
Acute-on -chronic liver failure Reactivation of hepatitis B Spontaneous reactivation of chronic hepatitis B presenting as to acute-on-chronic liver failure |
Hepatitis A Hepatitis B Hepatitis Liver Failure Hepatic Insufficiency End Stage Liver Disease Acute-On-Chronic Liver Failure Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections |
RNA Virus Infections Hepadnaviridae Infections DNA Virus Infections Liver Failure, Acute Tenofovir Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents |